Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Please choose your permissions
Mandatory field
Please enter your official email address
Research programme: viral vaccines - Pharos Biologicals
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
No
New Molecular Entity
No
Available For Licensing
Yes - Viral infections
Highest Development Phases
No development reported
Dengue; Influenza virus infections; Zika virus infection
Most Recent Events
28 Jun 2020
No recent reports of development identified for preclinical development in Zika-virus-infection in USA
28 Jun 2020
No recent reports of development identified for research development in Dengue in USA
28 Jun 2020
No recent reports of development identified for research development in Influenza-virus-infections in USA
Development Overview
Introduction
Pharos Biologicals is developing vaccines for the prevention of flavivirus and influenza infections, using Johns Hopkins University School of Medicine's proprietary lysosome-associated membrane protein (LAMP) DNA vaccine technology and other nano technologies. Preclinical research for Zika virus infection is ongoing in the US, with early research underway for dengue and influenza infections.
The LAMP technology utilises normal cellular mechanisms to enhance the immune response to the vaccine, which is comprised of antigen protein sequences are encoded as an antigen/LAMP chimera construct. The LAMP DNA vaccine is not a live virus vaccine, has a more rapid development time line, delivers the pathogen antigen directly to cell proteins that bring about immunological responses, and is highly stable.
Viral vaccines program is available for licensing (Pharos Biologicals website, May 2016).
As at June 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection in USA, research development in Dengue in USA, research development in Influenza-virus-infections in USA.
Company Agreements
In May 2016, Pharos Biologicals received exclusive worldwide license for a patented Lysosome-Associated Membrane Protein (LAMP) DNA vaccine technology and other nanotechnologies from Johns Hopkins University School of Medicine. Financial details of the deal were not disclosed[1].
Key Development Milestones
Pharos Biologicals is planning to initiate a phase I clinical trial in patients with Zika virus infection, by the end of 2016[1][2].
No recent reports of development identified for preclinical development in Zika-virus-infection in USA
Updated 28 Jun 2020
28 Jun 2020
Phase Change - No development reported
No recent reports of development identified for research development in Dengue in USA
Updated 28 Jun 2020
28 Jun 2020
Phase Change - No development reported
No recent reports of development identified for research development in Influenza-virus-infections in USA
Updated 28 Jun 2020
11 May 2016
Licensing Status
Research programme: viral vaccines - Pharos Biologicals is available for licensing as of 11 May 2016. http://pharosbiologicals.com./
Updated 11 May 2016
02 May 2016
Trial Update
Pharos Biologicals plans a phase I trial for Zika virus infections [1]
Updated 11 May 2016
02 May 2016
Licensing Status
Pharos Biologicals in-licenses Lysosome-Associated Membrane Protein (LAMP) DNA vaccine technology from Johns Hopkins University School of Medicine [1]
Updated 05 May 2016
02 May 2016
Phase Change
Early research in Dengue and Influenza virus infections in USA (unspecified route) [1]
Updated 05 May 2016
02 May 2016
Phase Change - Preclinical
Preclinical trials in Zika virus infection in USA (unspecified route) [1]
Updated 05 May 2016
References
Pharos Biologicals Conducting Tests of a Novel Zika Vaccine.
